This STAT story does a good job putting a single, unexpected experimental result using brain cancer immunotherapy into perspective. Its strongest points are that it avoids touting this one patient’s experience as any kind of broad “success,” calling it an “early inroad;’ emphasizing its “notorious” potential side effects; and most of all quoting sources outside City of Hope who made clear that, as one put it, the success was possibly a “flash in the pan.” Bravo. One thing that would have made the story stronger? Early on emphasizing how a single case study makes for weak evidence that an intervention works. See our six tips for writing accurately about cancer immunotherapy drugs.
Unlike the TIME story, this story included important voices of caution to help keep expectations in check. Starting with the headline, readers of this story are likely to come away with a more realistic perspective on this treatment. (Meanwhile, TIME’s headline was misleading: “Experimental Brain Cancer Treatment Is a Success.”)
As we noted in our review of TIME Magazine’s story as well: Although there may not yet be any accurate prediction of the cost of the particular therapy described for this single patient, it is generally well established and well documented that immunotherapies–particularly those that involve modifying a patient’s own immune cells–are many times more expensive than standard treatments, sometimes running to annualized costs in the hundreds of thousands of dollars. This story says nothing about the costs.
The article notes that the patient was in remission for seven months, but like the TIME article, says nothing specifically about what the patients tumor status was during those seven months. If the tumors shrunk, it would be at least useful to know the baseline measurements and degree of shrinkage and disappearance, as well as any improvements or (setbacks) in quality of life.
This was a tough call, but we’re leaning toward satisfactory.
On one hand, the STAT story does acknowledge the downsides, so far, of CAR-T therapy, by referring to the adverse events as “notorious” and providing a link for more information.
On the other hand, the story only mentions that severe side effects have occurred without telling us any of those side effects and what the side effects (if any) were for the one patient treated. Instead it says the patient’s side effects were “fairly innocuous” and quotes a researcher early in the story saying “it’s amazing how safe it was.” Yet, this hardly proves it’s safe.
The story does make it clear that this was an intervention tested in a single patient, and includes cautious statements from experts. This is a barely passing satisfactory–we think the story could have more emphatically said that any single case study cannot and should not be used to generalize the efficacy of any therapy until more reliable studies are done.
No mongering here regarding the brain cancer glioblastoma.
Job well done in quoting sources outside of the City of Hope investigators and putting the findings into cautious perspective throughout the article. If the story was to be done at all (still a debatable decision), this article makes the best of the context problem.
Very few details of conventional alternative treatments are included, but the story points out that glioblastoma is resistant to most treatment options. Still, the story should have noted that alternatives include surgery, radiation and chemotherapy.
The STAT story notes the availability of CAR-T commercially (by naming the companies) for blood cancers, and it quotes an outside source as essentially saying “don’t hold your breath” awaiting the viability of this treatment for glioblastoma.
The article does a brief but adequate job of describing what is newsworthy here–how this experimental CAR-T is being used for solid tumors for the first time.
The story possibly may have started with the news release, but it reflects useful additional outside reporting.
This story in STAT, like the one in TIME.com that we also reviewed, describes the successful, and apparently first positive response of a glioblastoma brain tumor to CAR-T therapy. This is an experimental immunotherapy that depends on on injections of modified immune cell proteins and that has had a few successes in blood cancers but essentially none in solid tumors, including those in the brain.
Described in a report in the The New England Journal of Medicine, the study was conducted and promoted by officials and physicians at the City of Hope Beckman Research Institute and Medical Center, an organization that has a somewhat unfortunate history of touting treatments as bringing about “miracles” and encouraging coverage of compelling individual cancer patient stories to support sometimes exaggerated claims of major advances in cancer treatment.
This STAT story does a better job than TIME of putting what is essentially a single, unexpected experimental result into perspective. Its strongest points are that it avoids touting this one patient’s experience as any kind of broad “success,” calling it an “early inroad;’ emphasizing its “notorious” potential side effects; and most of all quoting sources outside City of Hope who made clear that, as one put it, the success was possibly a “flash in the pan.” Bravo. One thing that would have made the story stronger? Early on emphasizing how a single case study makes for weak evidence. See our six tips for writing accurately about cancer immunotherapy drugs.
Unlike the TIME story (see our review), this story included important voices of caution to help keep expectations in check. Starting with the headline, readers of this story are likely to come away with a more realistic perspective on this treatment. (Meanwhile, TIME’s headline was misleading: “Experimental Brain Cancer Treatment Is a Success.”)
As we noted in our review of TIME Magazine’s story as well: Although there may not yet be any accurate prediction of the cost of the particular therapy described for this single patient, it is generally well established and well documented that immunotherapies–particularly those that involve modifying a patient’s own immune cells–are many times more expensive than standard treatments, sometimes running to annualized costs in the hundreds of thousands of dollars. This story says nothing about this.
The article notes that the patient was in remission for seven months, but like the TIME article, says nothing specifically about what the patients tumor status was during those seven months. If the tumors shrunk, it would be at least useful to know the baseline measurements and degree of shrinkage and disappearance, as well as any improvements or (setbacks) in quality of life.
This was a tough call, but we’re leaning toward satisfactory.
On one hand, the STAT story does acknowledge the downsides, so far, of CAR-T therapy, by referring to the adverse events as “notorious” and providing a link for more information.
On the other hand, the story only mentions that severe side effects have occurred without telling us any of those side effects and what the side effects (if any) were for the one patient treated. Instead it says the patient’s side effects were “fairly innocuous” and quotes a researcher early in the story saying “it’s amazing how safe it was.” Yet, this hardly proves it’s safe.
See our tips for reporting accurately about the harms, side effects and risks of immunotherapy.
The story does make it clear that this was an intervention tested in a single patient, and includes cautious statements from experts. This is a barely passing satisfactory–we think the story could have more emphatically said that any single case study cannot and should not be used to generalize the efficacy of any therapy until more reliable studies are done.
No mongering here regarding the brain cancer glioblastoma.
Job well done in quoting sources outside of the City of Hope investigators and putting the findings into cautious perspective throughout the article. If the story was to be done at all (a debatable decision), this article makes the best of the context problem.
Very few details of conventional alternative treatments are included, but the story points out that glioblastoma is resistant to most treatment options. Still, the story should have noted that alternatives include surgery, radiation and chemotherapy.
The STAT story notes the availability of CAR-T commercially (by naming the companies) for blood cancers, and it quotes an outside source as essentially saying “don’t hold your breath” awaiting the viability of this treatment for glioblastoma.
The article does a brief but adequate job of describing what is newsworthy here–how this experimental CAR-T is being used for solid tumors for the first time.
The story possibly may have started with the news release, but it reflects useful additional outside reporting.
Systematic, Criteria-Driven
New article by @UnhealthyAlcDrg & @garyschwitzer is 💯on point. This sums it up perfectly: "The COVID-19 pandemic has created perhaps the most challenging time for science communication in decades." #hcldr
Communicating Science in the Time of a Pandemic https://ja.ma/3ftMYpT
Important piece: "Communicating Science in the Time of a #Pandemic" https://jamanetwork.com/journals/jama/fullarticle/2768397 by @UnhealthyAlcDrg & @garyschwitzer via @JAMA_current
Needed: < hype & > caution
Science & health community: "reflect on how the words and the data matter, & then act accordingly."
All science communicators should read this very useful and smart about 1-page article "Communicating Science in the Time of a Pandemic" published in the JAMA written by Richard Saitz (@UnhealthyAlcDrg) & Gary Schwitzer (@garyschwitzer). @hsfi https://jamanetwork.com/journals/jama/fullarticle/2768397 #EBM #COVID
3
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like